Your session is about to expire
← Back to Search
Phosphodiesterase type 5 inhibitor
1 for Prostate Cancer (HBOT Trial)
Phase 4
Waitlist Available
Led By James Graydon, MD
Research Sponsored by Hartford Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
All Individual Drugs Already Approved
Approved for 5 Other Conditions
Pivotal Trial
Drug Has Already Been Approved
Summary
The purpose of this study is to determine if adding hyperbaric oxygen therapy, a therapy that delivers oxygen under slight pressure, to a drug treatment of PDE5I (such as Viagra, Levitra, Cialis)for men following surgery for prostate cancer will result in more men being able to continue to have erections.
Eligible Conditions
- Prostate Cancer
- Erectile Dysfunction
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
Trial Design
2Treatment groups
Active Control
Placebo Group
Group I: 1Active Control1 Intervention
Group II: 2Placebo Group1 Intervention
Find a Location
Who is running the clinical trial?
Hartford HospitalLead Sponsor
138 Previous Clinical Trials
19,297 Total Patients Enrolled
1 Trials studying Prostate Cancer
85 Patients Enrolled for Prostate Cancer
James Graydon, MDPrincipal InvestigatorHartford Hospital
Share this study with friends
Copy Link
Messenger